Research & development

CRC discovery contributes to asthma drug development

16 December, 2005

A discovery made at WEHI by the Cooperative Research Centre for Cellular Growth Factors (CRC-CGF) has led to the selection of an antibody-based drug for full preclinical development as a potential new treatment for asthma and other respiratory diseases.

Study suggests drug may reverse psychosis

01 December, 2005

Cannabis, a drug believed to increase the risk of psychosis in users, contains a compound that may be able to reverse psychotic behaviour, Monash researchers have found.

Collaborators seek parasite invasion blockers

18 November, 2005

A malaria research team, including WEHI Structural Biologist, Professor Ray Norton, has received a US$1 million grant from the US National Institutes of Health to develop more effective malaria treatments.

Method to detect potential bioterrorism agent

08 November, 2005

A new combination of analytical chemistry and mathematical data analysis techniques allows the rapid identification of the species, strain and infectious phase of the potential biological terrorism agent Coxiella burnetii. The bacterium causes the human disease Q fever, which can cause serious illness and even death.

Cellular emotions

07 November, 2005

University of Queensland researchers have identified a protein that is crucially involved in how memories are stored and processed, paving the way for new strategies to treat conditions of certain mental disorders.

Adult stem cells found in uterus

04 November, 2005

Dr Caroline Gargett from Monash Institute of Medical Research (MIMR) has discovered adult stem cells in the uterus that can be grown into bone, muscle, fat and cartilage and her research has been hailed as a major medical and scientific development by international reproduction experts.

Carbene work could give cheaper drugs

02 November, 2005

Chemists at the University of California, Riverside have synthesised a new class of carbenes - molecules that have unusual carbon atoms - that is expected to have wide applications in the pharmaceutical industry, ultimately resulting in a reduction in the price of drugs.

Insulin synthesis without using E.coli

30 October, 2005

If living cell is replaced by a test-tube with DNA and a set of substances, it is possible to get proteins in a more simple and inexpensive way. That was done by Russian biochemists synthesising insulin without help of transgene Escherichia coli.

Development of a quick detection method for complex immune analytes

29 October, 2005

An analysis method permitting the simultaneous quantification of numerous parameters in the immune system was recently presented at the Campus Vienna Biocenter. The technology, which has been developed by Bender MedSystems, is based on the principle of a widespread analysis device and thus allows for rapid implementation in daily laboratory life. It thus succeeds in satisfying the growing demand at clinical and pharmaceutical organisations for increasingly efficient analysis methods at favourable costs.

Genes may predict response to ADHD medication

27 October, 2005

Testable genetic differences might be used to predict the effectiveness of a medication commonly prescribed to treat attention deficit hyperactivity disorder, a new study suggests.

Oncogene may lead to predictive test

25 October, 2005

Researchers at The University of Texas MD Anderson Cancer Centre say they have discovered a potential oncongene in ovarian cancer, which is the leading cause of gynaecological cancer death in US women.

Portable generic risk detection

24 October, 2005

A portable biosensing device based on micro- and nanotechnologies is expected to help doctors rapidly and accurately forewarn patients of their genetic risk of developing diseases such as cancer.

Microchips for in vitro diagnostics

21 October, 2005

DiagnoSwiss and bioMerieux have signed an exclusive licence agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics.

Investment to develop pain therapy

20 October, 2005

A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative pain therapy.

Salivary bacteria as indicators of oral cancer

18 October, 2005

Patients suffering from oral cancer have increased levels of certain bacteria in their saliva, according to research published in the Open Access journal, Journal of Translational Medicine. Six common species of bacteria were found at significantly higher levels in the saliva of patients with oral squamous cell carcinoma (OSCC) than in the saliva of healthy individuals. The researchers were able to use three of the six species as a diagnostic tool to predict more than 80% of oral cancer cases. These preliminary findings indicate that three species of bacteria may be incidentally or causally linked with OSCC, and if so detection of these species could be used as a simple, rapid and non-invasive saliva test to diagnose oral cancer.

  • All content Copyright © 2022 Westwick-Farrow Pty Ltd